Home > Healthcare > Biotechnology > Biotechnology R&D > Nucleic Acid Isolation & Purification Market

Nucleic Acid Isolation & Purification Market Share

Report ID: GMI7608
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Nucleic Acid Isolation &s Purification Market Share

The nucleic acid isolation and purification industry is characterized by diverse players competing in the industry, leveraging their research capabilities and global presence. Strategic collaborations, product innovations, and regulatory compliance further strengthen their positions. The market is characterized by ongoing technological advancements and a focus on developing safer and more effective instruments and kits, intensifying the competitive dynamics in the healthcare sector.

Nucleic Acid Isolation &s Purification Market Companies

The prominent players operating in the nucleic acid isolation and purification industry is as mentioned below:

QIAGEN N.V.
Thermo Fisher Scientific Inc.
Illumina Inc.
Danaher Corporation
F. Hoffmann La Roche Ltd
Merck KGaA
Agilent Technologies Inc.
Bio-Rad Laboratories
Takara Bio Inc.
Promega Corporation
New England Biolabs
Abcam plc.
PCR Biosystems

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Nucleic acid isolation & purification industry size was USD 5 billion in 2023 and is expected to reach USD 9.9 billion by end of 2032 due to the escalating demand for advanced diagnostic techniques, particularly in genomics and precision medicine.

The reagents & kits product segment may record USD 7.3 billion by 2032 driven by rising innovations to offer enhanced performance, automation capabilities, and compatibility with high-throughput systems.

Nucleic acid isolation & purification industry size from the diagnostics application segment reached USD 1.7 billion in 2023 due to higher deployment for the identification of pathogens in routine sample processing.

North America held 37.8% of the global nucleic acid isolation and purification market share in 2023 owing to the strong presence of leading biotechnology and pharmaceutical companies along with significant government investments in genomics and molecular biology research.